LSI

Traditional ECG interpretation approaches are inadequate due to their frequent inaccuracies, lengthy result turnaround times, and lack of accessibility, particularly in remote or resource-limited settings. AccurKardia is addressing these issues with its flagship product, the AccurECG™ Analysis System. It’s an FDA-cleared, cloud-based, device-agnostic, and fully automated electrocardiogram (ECG) interpretation software platform. The software provides an array of benefits, such as beat-by-beat analysis, ventricular/supraventricular ectopic beat detection, heart rate measurement, and automated interpretation of 13 different heart rhythms including sinus tachycardia, sinus bradycardia, atrial fibrillation, and atrial flutter, among others. The fully automated output of AccurECG™ improves clinicians’ review efficiencies and enables prompt treatment of patients, with results delivered in minutes instead of days or weeks. It is indicated for adults aged 22 and older. Catch the latest from AccurKardia. Tune into Juan C Jimenez and Moin Hussaini’s Studio Interview and presentation from LSI USA ‘24 to learn more about AccurKardia’s recent progress. Available now on our website and YouTube channel.

In anticipation of LSI Asia ‘25, we’re showcasing the incredible innovation from the #LSIAlumni in Asia. It’s the innovators like these that get us excited to bring LSI Asia to Singapore in June 2025. Today, we’re showcasing Vyasaraj Manakari, Co-Founder & CEO of Magloy Tech. The company is pioneering the future of medical implants with its innovative bioresorbable magnesium technology. Magloy Tech’s flagship product, ResoMag®, is an advanced bioresorbable magnesium technology offering unparalleled mechanical stability and controlled degradation thereby fostering efficient bone healing. Designed to dissolve naturally, their implants, including state-of-the-art cranial plating systems and compression screws, leave healthy bone tissue, significantly lowering the risks associated with traditional implants. To learn more about Magloy Tech, watch Vyasaraj’s full video presentation from LSI USA ‘24. Available on our website and YouTube channel. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

AI is poised to revolutionize healthcare, but what will it take to integrate it into clinical workflows? Our recent panel at LSI USA '24 tackled this question head-on. Our expert panelists discuss the real-world challenges and successes of AI adoption in healthcare, from data quality and regulatory hurdles to the importance of clinical trials and the human element in AI integration. Tune into the full panel to hear advice and nuanced perspectives from: • Natasha Allen (Moderator), Partner, Foley & Lardner LLP • Sascha Berger, Healthcare Investor • Robert J. Krummen, CEO, Vektor Medical, Inc. • Daniel Hawkins, CEO, Vista.ai The full panel, “Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?” is available on our website and YouTube channel.

Last week, Henry Peck challenged 10 of the top investors in our industry to weigh the relative importance of "founder quality vs market opportunity" in their investment process and explain their rationale. The result is a must-read article for Medtech and Healthtech operators who are raising capital and want a look behind the curtain into venture capital decision-making. The full article “Balancing Act: How Do Investors Weigh Founders Versus Markets in Medtech and Healthtech Venture?” is available at the link below: https://lnkd.in/gzF66xpC Thank you to our guest contributors to this article: • Dr. Luc Marengere, Managing Partner at TVM Capital Life Science • Dr. Gal Noyman - Veksler, Partner at LionBird • Soyoung Park, General Partner at 1004 Venture Partners, Venture Partner at VU Venture Partners • Armen Vidian, Founder and Managing Partner at Recode Ventures • Adam Rosenwach, Chief Business Officer at Deerfield Catalyst • Owen Willis, Founder and General Partner at Opal Ventures • Kevin Chu, Principal at F-Prime Capital • Dr. Josh Makower, Director and Co-Founder of the Stanford Byers Center for Biodesign and the Founder and Executive Chairman of ExploraMed • David Kereiakes, Managing Partner at Windham Capital Partners • Scott Huennekens, Former Medtech CEO/Entrepreneur, current Investor, & Executive Chairman via Front Foot Ventures

Every patient undergoing Transcatheter Aortic Valve Replacement (TAVR) faces the devastating risk of stroke from blood laden debris. Transverse Medical Inc has developed the POINT-GUARD™ Cerebral Embolic Protection device to address the unmet need for Full-Brain protection and eliminate the clinical problem of periprocedural Stroke and Silent Stroke in Structural Heart Procedures, like TAVR. The POINT-GUARD™ full brain protection solution provides maximum coverage and filtering of cerebral embolic debris (particles) during cardiovascular procedures. By providing maximum coverage and complete cerebral embolic protection, Transverse Medical effectively addresses the unmet clinical need to safeguard the entire brain from stroke while allowing the physician operators to safely treat their patients' heart. During LSI USA ‘24 we had the pleasure of sitting down with Eric Goslau, President & CEO of Transverse Medical, for a Studio Interview to discuss how POINT-GUARD™ is minimizing and eliminating the risk of stroke during cardiovascular procedures. The full interview is available on our website and YouTube channel. Want to join us for a Studio Interview at LSI Europe ‘24 this September? Reach out to our team today while space is still available.

Coramaze Technologies (#LSIEurope24 Innovator) develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel the company promotes health equity by offering a solution that is easy to use, fast (procedure time below 30 minutes), and effective. They aim to empower physicians in both existing and new markets, allowing them to treat patients who cannot be served with existing technologies. Tricuspid Regurgitation (TR) is a life-threatening condition, with a 3-year survival rate in severe cases of less than 50%. Despite affecting more than 4.8 million patients in the EU and US, most TR patients remain untreated. The TriPair system is a transcatheter tricuspid edge-to-spacer technology, designed to be anchored atraumatically to the right atrium. The device is intended to be easily placed in a procedure taking less than thirty minutes. TriPair is agnostic of valve morphology and can be retrieved if necessary. We’re excited to announce that CEO Jochen Reinöhl, MD, MSc, has been selected to present Coramaze Technologies at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Jochen and learn more about Coramaze.

In anticipation of LSI Asia ‘25, we’re showcasing the incredible innovation from the #LSIAlumni in Asia. It’s the innovators like these that get us excited to bring LSI Asia to Singapore in June 2025. Today, we’re showcasing Ken-ichi MARUYAMA CEO & Founder of GORYO CHEMICAL, INC, a clinical-stage biotechnology company providing new fluorescent probes for cellular analysis, assay, and imaging. The company is known for creating innovative fluorescent probes, including those for oxidative stress-related reagents and enzyme activity detection reagents. These probes are used extensively in cell biology and diagnostics to visualize diseases and guide treatments, such as in fluorescent image-guided surgery for cancer detection. These probes enhance the visualization of minute cancer cells during surgery, aiding in the complete removal of cancerous tissues. To learn more about Goryo Chemical, watch the full video presentation from LSI USA ‘24. Available on our website and YouTube channel. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

Is FDA Breakthrough Device Designation worth it? You might be surprised by the answer. During this LSI USA '24 panel, the consensus among panelists was that the FDA Breakthrough Device Designation may not be as beneficial as it seems. However, if you still choose to pursue it, the panelists offer valuable advice for those considering this path. Tune into the full panel to hear the advice and nuance from innovators, attorneys, and regulatory experts who have navigated the strategic and operational challenges of winning FDA Breakthrough Designation. The full panel, “FDA Breakthrough Designation: ROI and Considerations With Shifts in Coverage” is available on our website and YouTube channel. Featured panelists:  • Etienne Nichols (Moderator), Head of Industry Insights & Education at Greenlight Guru • Kwame Ulmer, Managing Partner at MedTech Impact Partners • Carolina Aguilar is Co-Founder & CEO of INBRAIN Neuroelectronics • Nathan Beaver, Partner at Foley & Lardner LLP • Lishan Aklog, MD is Chairman & CEO at Lucid Diagnostics

The decision to launch LSI Asia is a response to the evolving dynamics of the global Medtech industry and our growing global community. Over the past few years, we have witnessed the Asia Pacific region emerge as a hotbed for innovation, capital, manufacturing, and business development. According to LSI's Global Market Analysis and Projections (MAP) Database, APAC is the second largest region for Medtech, with a market size of $131 billion in 2023. What's even more notable is the projected CAGR (2023 - 2028). Our analysts project an 8.4% CAGR, nearly double the growth rate of both the United States and Europe. There is a robust set of procedures in the region with volumes growing at 10% CAGR, according to our Global Procedure Volumes Database, including: • Transcatheter Valve Replacements • CRT-D Implants • Tracheostomies, and Radical Neck Dissections • Laparoscopic Appendectomies, Hernia Repairs, and Bariatric • Neurostimulation Implant Procedures • Breast-conserving surgeries (cancer) • Therapeutic endoscopies (bladder) • Revision Hip Arthroplasties, Total Hip Replacement, Revision and Total Knee Replacement, Extremity Fracture Repair Want to join us at LSI Asia ‘25 or learn more about our comprehensive Medtech Market Intelligence platform? Visit our website or reach out to our team today. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore. Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open.

Last Call for Presenting Company Applications With less than 2 months to go before #LSIEurope24, we're announcing our last call for presenter applications and giving you a preview of the first 150 innovators selected to present at LSI Europe ‘24 this September in Sintra, Portugal. Here’s a sneak peek of 30 innovators presenting this September: • Moshe Barel — Acculine • Laetitia Messner — Quantum Surgical • Olivier BENOIT — Ciliatech • Natalie Garzorz-Stark — Dermagnostix • Jenny Hoffmann, PhD — Biorithm • Mathieu Rimaud — Twinsight • Jokke Mäki — GlucoModicum • Manios Dimitrakakis — Panda Surgical • Ameera Patel — TidalSense • Melcher Frankema — Ivy Medical • Pau Rodríguez — Methinks AI • Bryan Lord — Pristine Surgical • Efraín Torres, PhD — Adialante • Martin Herman — Powerful Medical • Philippe Bencteux MD — INEN Robotics • Caitlin Morse — BrainSpace • Wouter Markus — Haermonics • Michel Vanbrabant — iSTAR Medical • Rutger Flink — PulmoTech • Andrew Cameron — FeelTect • Simone Bottan — HYLOMORPH • Mary-Beth Brinson — Cyban • John Wheeler — Cranial Devices • Emiliano Lepore — RECORNEA • Claartje Ypma — Augmedit • Yosef Safi Harb — Happitech • Olivier Pierron — Cardiawave • Ryan DeBoer — The Shape Sensing Company • Joseph W. Rafferty — VESTECK • Frans Cromme — ViCentra Interested in speaking, presenting, or exhibiting at LSI Europe '24? Join nearly 1,000 global Medtech and Healthtech leaders in Sintra, Portugal this September 16-20th. Apply on our website today while space is still available.